Pharvaris Summarized The Presentations For The American Academy Of Allergy, Asthma & Immunology Annual Meeting For Deucrictibant For On-Demand And Prophylactic Treatment Of Bradykinin-mediated Angioedema
Benzinga Newsdesk 8 months ago
BiotechHealth CareGeneral
RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and
- RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacks
- Final CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant for the prevention of HAE attacks; single-dose, sustained therapeutic exposure with deucrictibant extended-release tablet supports once-daily prophylactic application